Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

GlaxoSmithKline Lifts Stake In Theravance With $213 Mln Investment - Quick Facts

RELATED NEWS
Trade THRX now with 

Biopharmaceutical company Theravance, Inc. (THRX: Quote) on Monday said it has entered into a stock purchase agreement, under which its drug development partner GlaxoSmithKline Plc (GSK: Quote, GSK.L) agreed to acquire 10 million of its shares at a price of $21.2887 per share. The total investment for the acquisition would be $212.89 million.

Following the acquisition, British drug giant GSK would own around 25.81 million shares of Theravance common stock, which would increase GSK's ownership to approximately 26.8 percent from about 18.3 percent of Theravance capital.

The company noted that the price per share was determined based upon a 7.5 percent premium to the volume-weighted average price per share of Theravance stock over the five-day period ending March 30, which was $19.8034.

The deal would complete shortly after the Theravance Annual Meeting, subject to certain closing conditions, including approval of Theravance's stockholders.

GSK expects to continue to account for its total stake in Theravance as an investment held at fair value, due to the existing governance agreement which places limitations on GSK's voting rights.

Click here to receive FREE breaking news email alerts for THERAVANCE, INC. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Swiss drug maker Roche Holding said a late-stage trial of its breast cancer drug Kadcyla did not provide superior results compared with an existing therapy. FCA US, until recently known as Chrysler, said Friday it is recalling 257,000 Dodge Ram pickups. The auto maker says the rear axle pinion nut on certain model year 2005 Dodge Ram 1500 trucks may loosen due to an undersized spline on the pinion gear. If the pinion nut loosens, the rear axle may... This medical device company has a very impressive track record of growing business over the past decade. increasing sales from $490.2 million in 2004 to $1.72 billion this year. The Silicone Hydrogel daily disposable lens portfolio constitutes a major avenue for growth.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.